Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Early engraftment and full-donor chimerism after single-cord blood plus third-party donor dual transplantation in patients with high-risk acute leukemia

Bone Marrow Transplantation volume 49, pages 145–147 (2014)Cite this article

Subjects

Umbilical cord blood (UCB) has emerged as a safe and effective hematopoietic cell (HC) source for adult acute leukemia patients who lack an HLA-matched donor.1 While UCB transplants offer advantages compared with other allogeneic HC sources, their hematopoietic engraftment and immune reconstitution are delayed and limited by the number of HCs contained in the UCB unit together with donor-recipient HLA disparities.2 A dual transplant strategy combining UCB plus third-party donor (TPD) HC (UCB–TPD) pioneered at Hospital Puerta de Hierro in Madrid has been shown to improve early outcomes after UCB transplantation by hastening hematopoietic recovery.3 Here, we present an independent series of 13 consecutive high-risk myelodysplastic syndrome (MDS)/AML and ALL patients, median age 45 years (20–64) and weight 71 Kg (56–104), who received a myeloablative UCB–TPD dual transplant in our center from February 2009 to January 2013. Patients lacked a matched related or unrelated donor, were in advanced stage and heavily pretreated: seven refractory to ⩾1 line of chemotherapy, three relapsed after a previous HC transplant, and two had active AML (9 and 22% blasts) prior to UCB–TPD transplant (Table 1). Our non-TBI chemotherapy-based myeloablative4 conditioning and GVHD prophylaxis regimen included BU (12 mg/kg), CY (100 mg/kg), fludarabine (120 mg/m2), thymoglobulin (4 mg/kg), CsA and a short course of methylprednisolone. Patients received UCB units with 1–3 out of 6 HLA mismatches (A, B antigenic; DR allelic), a median post-thawing total nucleated cell count of 2.62 × 107/kg (1.39–5.8) and CD34+ cell count of 0.98 × 105/kg (0.35–2.26),5 followed by a median 4.96 × 106/kg miltenyi-purified TPD CD34+ cells (3.62–11.90) with <1 × 104/kg CD3+ cells (Table 2). TPD were haploidentical relatives in all cases but one, patient no. 9, whose TPD was a fully mismatched brother. G-CSF (30MU) was administered from day +1 until sustained neutrophil engraftment >1 × 109/L.

Table 1 Patient demographics, disease characteristics and clinical follow-up
Full size table
Table 2 Characteristics of cellular products and kinetics of donor chimerism
Full size table

All patients engrafted neutrophils >0.5 × 109/L and platelets >20 × 109/L by median days +12 (range, 10–17) and +23 (range, 12–105), respectively. Twelve cases (92%) achieved full-donor chimerism as early as 2 weeks after UCB–TPD transplant. Donor chimerism and engraftment were initially derived from the TPD in all cases, and shifted rapidly to UCB in all evaluable patients but one, case no. 10, whose post-thawing UCB viability and cell counts (Table 2) were low, failing to engraft the CBU and remaining in CR and sustained haploidentical donor chimerism until his most recent follow-up, 15 months after transplant.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Sanz MA . Cord-blood transplantation in patients with leukemia—a real alternative for adults. N Engl J Med 2004; 351: 2328–2330.

    Article  CAS  Google Scholar 

  2. Rocha V, Gluckman E . Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft and transplantation related factors. Eurocord-Netcord registry and European Blood and Marrow Transplant Group. Br J Haematol 2009; 147: 262–274.

    Article  CAS  Google Scholar 

  3. Fernández MN . Improving the outcome of cord blood transplantation: use of mobilized HSC and other cells from third party donors. Review. Br J Haematol 2009; 147: 161–176.

    Article  Google Scholar 

  4. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628–1633.

    Article  Google Scholar 

  5. Gluckman E, Rocha V . Donor selection for unrelated cord blood transplants. Curr Opin Immunol 2006; 18: 565–570.

    Article  CAS  Google Scholar 

  6. Miller AN, Glode A, Hogan KR, Schaub C, Kramer C, Stuart RK et al. Efficacy and safety of ciprofloxacin for prophylaxis of polyoma BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 2011; 17: 1176–1181.

    Article  CAS  Google Scholar 

  7. Kwon M, Balsalobre P, Serrano D, Perez Corral A, Buño I, Anguita J et al. Single cord blood combined with HLA-mismatched third party donor cells: comparable results to matched unrelated donor transplantation in high-risk patients with hematologic disorders. Biol Blood Marrow Transplant 2013; 19: 143–149.

    Article  Google Scholar 

  8. Liu H, Rich ES, Godley L, Odenike O, Joseph L, Marino S et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood 2011; 118: 6438–6445.

    Article  CAS  Google Scholar 

  9. Childs RW . Combined cord blood and haploidentical CD34+ cell transplantation improves transplant outcome for patients with treatment-refractory severe aplastic anemia [abstract]. 10th International Cord Blood Symposium 36, 2012 Available at http://www.cordbloodsymposium.org/.

  10. Lindemans CA, Kuball JHE, te Boome LCJ, Versluys AB, Bierings MB, Boelens JJ . Coinfusion of haploidentical donor stem cells with unrelated cord blood[abstract]. 10th International Cord Blood Symposium 5, 2012 Available at http://www.cordbloodsymposium.org/.

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Catalan Institute of Oncology (ICO)—Hospital Duran i Reynals, Barcelona, Spain

    I Sánchez-Ortega, M Arnan, B Patiño & R F Duarte

  2. Group of Hematological Malignancies, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain

    I Sánchez-Ortega, M Arnan, B Patiño & R F Duarte

  3. Laboratori d'Immunobiologia per a la Reçerca i Aplicacions Diagnòstiques (LIRAD), Banc de Sang i Teixits, Barcelona, Spain

    M J Herrero

  4. Cell Therapy Unit and Cord Blood Bank, Banc de Sang i Teixits, Barcelona, Spain

    S Querol

Authors
  1. I Sánchez-Ortega
    View author publications

    Search author on:PubMed Google Scholar

  2. M Arnan
    View author publications

    Search author on:PubMed Google Scholar

  3. B Patiño
    View author publications

    Search author on:PubMed Google Scholar

  4. M J Herrero
    View author publications

    Search author on:PubMed Google Scholar

  5. S Querol
    View author publications

    Search author on:PubMed Google Scholar

  6. R F Duarte
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to R F Duarte.

Ethics declarations

Competing interests

All authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sánchez-Ortega, I., Arnan, M., Patiño, B. et al. Early engraftment and full-donor chimerism after single-cord blood plus third-party donor dual transplantation in patients with high-risk acute leukemia. Bone Marrow Transplant 49, 145–147 (2014). https://doi.org/10.1038/bmt.2013.113

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/bmt.2013.113

This article is cited by

Search

Advanced search

Quick links